Everolimus in cardiac-transplant recipients.
Banas
Bernhard
B
Böger
Carsten
C
Krämer
Bernhard
B
D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D003327:Coronary Disease / Q000517:prevention & control; D003331:Coronary Vessels / Q000473:pathology; D000068338:Everolimus; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000139:chemically induced* / Q000453:epidemiology; D020123:Sirolimus / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D000068338:Everolimus; D001379:Azathioprine; D020123:Sirolimus